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ABSTRACT
SJG-136, a pyrrolo[2,1-c][1,4]benzodiazepine (PBD)
dimer, is a highly efficient interstrand crosslinking
agent that reacts with guanine bases in a 50-GATC-30
sequence in the DNA minor groove. SJG-136 cross-
links form rapidly and persist compared to those
produced by conventional crosslinking agents such
as nitrogen mustard, melphalan or cisplatin which
bind in the DNA major groove. A panel of Chinese
hamster ovary (CHO) cells with defined defects in
specific DNA repair pathways were exposed to the
bi-functional agents SJG-136 and melphalan, and
to their mono-functional analogues mmy-SJG and
mono-functional melphalan. SJG-136 was >100 times
more cytotoxic than melphalan, and the bi-functional
agents were much more cytotoxic than their respect-
ivemono-functionalanalogues.Cellularsensitivityof
both SJG-136 and melphalan was dependent on the
XPF-ERCC1 heterodimer, and homologous recomb-
ination repairfactorsXRCC2 and XRCC3. The relative
level of sensitivity of these repair mutant cell lines to
SJG-136 was, however, significantly less than with
major groove crosslinking agents. In contrast to
melphalan, there was no clear correlation between
sensitivitytoSJG-136andcrosslinkunhookingcapa-
citymeasuredusingamodifiedcometassay.Further-
more,repairofSJG-136crosslinksdidnotinvolvethe
formation of DNA double-strand breaks. SJG-136
cytotoxicity is likely to result from the poor
recognition of DNA damage by repair proteins result-
ingintheslowrepairofbothmono-adducts andmore
importantly crosslinks in the minor groove.
INTRODUCTION
DNAinterstrandcrosslinks(ICLs)arecriticalcytotoxiclesions
individing cells (1,2). Many commonlyused anti-cancerdrugs
are ICL agents. These include nitrogen mustards, platinum
compounds, chloroethylnitrosoureas, alkylalkanesulphonate
and mitomycin C. Rational approaches continue to produce
more efﬁcient DNA interstrand crosslinking agents and novel
tumourtargetingstrategies.Pyrrolo[2,1-c][1,4]benzodiazepine
(PBD) is a family of anti-tumour antibiotics which include
anthramycin, DC-81 and tomaymycin that are produced by
various Streptomyces strains (3). These agents covalently bind
guanine N2 in the minor groove of DNA and block trans-
cription in a sequence-dependent manner (4). In an attempt
to improve anticancer efﬁcacy, two PBD monomers have
been linked via their C8-positions to form dimers with high
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 interstrand crosslinking efﬁciency (5,6). Second generation
PBD dimers include SJG-136 (Figure 1), which is a highly
efﬁcient interstrand crosslinking agent that actively recognizes
50-PuGATCPy-30 sequences in the DNA minor groove (7–9).
When tested in vitro in the National Cancer Institute (NCI)
60 human tumour cell line panel, SJG-136 exhibited a unique
cytotoxicity proﬁle when compared with other ICL agents
used clinically (i.e. was COMPARE negative) (9). In human
tumour cells, crosslinks form rapidly and persist compared to
those produced by conventional agents, e.g. melphalan (9).
SJG-136 also displayed potent activity against several
human tumours in vivo (10), and phase I clinical trials are
currently underway.
The ability to repair DNA ICLs is a critical factor deter-
mining cytotoxicity. Using Chinese hamster ovary (CHO)
cells as a model system, we and others have previously
shown that the increased cytotoxic effects of interstrand
crosslinks induced by cisplatin and the nitrogen mustard
mechlorethamine are associated with defects in the XPF-
ERCC1 heterodimer component of the nucleotide excision
repair (NER) pathway and in XRCC2 and XRCC3 which
are Rad51 paralogues involved in the homlogous recom-
bination repair (HRR) pathway (11–13). ICLs pose a serious
problem for all cell types since genetic material is altered
on both strands. The specialized role of the XPF-ERCC1
structure-speciﬁc nuclease in ICL repair has yet to be fully
characterized, but several studies have indicated a role for
this heterodimer during the incision of ICLs in both biochem-
ical and cellular assays (12,14–17). Although the exact role of
XRCC2 and XRCC3 has not been elucidated, recent biochem-
ical data indicate that these Rad51 paralogues are essential for
promoting Rad51-catalyzed DNA strand exchange during
homologous recombination (18–21). A further complication
after treatment with some crosslinking agents is the generation
of DNA double-strand breaks (DSBs) (12,13). Whether or not
these represent a direct ICL repair intermediate has not been
fully established (22). It has been suggested that they arise
whenreplicationforksencounterICLs.Incellular DNA,DSBs
are evident after mechlorethamine treatment only in dividing
cells. DNA DSBs have not, however, been detected in actively
dividing cells after treatment with cisplatin (13). With the
nitrogen mustard mechlorethamine, we have shown XRCC2
and XRCC3 to be required for the repair of these types of
DSBs (12).
In this study, we have investigated the contribution of
NER, HRR and non-homologous end-joining (NHEJ) to the
cytotoxicity of SJG-136. A panel of CHO cells with deﬁned
defects in speciﬁc DNA repair pathways were exposed to
the bi-functional anticancer agents SJG-136 and melphalan,
and to their mono-functional analogues mmy-SJG and mono-
functional melphalan (Figure 1). Melphalan is a nitrogen
mustard chemotherapeutic that induces DNA ICLs in the
major groove of DNA and is used clinically in the treat-
ment of several cancers including multiple myeloma (23).
The mono-functional analogues mono-melphalan (24,25)
and mmy-SJG are capable of producing mono-adducts in the
major and minor groove, respectively but not DNA ICLs.
These agents were included in this investigation in order to
understand the importance of ICLs with respect to cytotoxicity
of both melphalan and SJG-136.
MATERIALS AND METHODS
Cell culture
Cell lines used in this study are listed in Table 1. AA8, UV23,
UV42, UV61 and UV96 were obtained from Dr M. Stefanini
(Istituto di Genetica Biochimica et Evoluzionistics, Pavia,
Italy), UV135 was purchased from the American Tissue
Culture Collection. V79, irs1, irs1SF, CHO-K1 and xrs5 cell
lineswere kindly provided by Prof J. Thacker(MRC Radiation
and Genome Stability Unit, Harwell, UK). All cell lines were
maintained as a monolayer in F12-Ham HEPES medium
(Sigma, Poole, UK) supplemented with 2 mM glutamine and
10% fetal calf serum (Autogenbioclear, Wiltshire, UK). Cells
weregrownat37 Cina5%CO2incubatorandharvestedusing
trypsin EDTA 1· solution (Autogenbioclear, Wiltshire, UK).
Chemicals and drugs
Melphalan (Sigma, Poole, UK) was dissolved in ethanol with
0.5% conc. HCl. Mono-melphalan was prepared as described
previously (24). SJG-136 and mmy-SJG were synthesized as
described in (7,8) and stock solutions prepared in methanol.
Figure 1. Structures of melphalan, mono-melphalan, SJG-136 and mmy-SJG.
Table 1. Chinese hamster ovary (CHO) cell lines
Mutant cell line Parent cell line Defective gene
UV23 AA8 XPB
UV42 AA8 XPD
UV47 AA8 XPF
UV61 AA8 CSB
UV96 AA8 ERCC1
UV135 AA8 XPG
irs1 V79 XRCC2
irs1SF AA8 XRCC3
xrs5 CHO-K1 XRCC5
3284 Nucleic Acids Research, 2005, Vol. 33, No. 10
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 The structures of the drugs used in this study are shown in
Figure 1. All other reagents were from Sigma unless otherwise
stated.
Growth inhibition assay
Cytotoxicity was determined following a 1 h drug incubation
using the sulforhodamine B (SRB) growth inhibition assay,
described in detail previously (12,13). Growth inhibition was
measured by quantifying the number of cells three days after
drug exposure.
Clonogenic survival assay
A total of 200 exponentially growing CHO cells were plated
in triplicate 90-mm plastic Petri dishes and incubated for
5 h to allow for cellular attachment. For clonogenic survival,
attached single cells were treated with different concentra-
tions of melphalan or SJG-136 for 1 h at 37 C in serum-free
medium. Cells were washed and incubated for 7–9 days until
visible colonies of more than 100 cells were obtained. Cells
were then stained with 1% methylene blue and the number of
colonies in each dish counted. Standard procedures were used
to measure plating efﬁciency and the surviving fraction. For
untreated cells, plating efﬁciencies were between 0.4 and 0.8,
and the surviving fraction normalized to 1.
Induction and repair of DNA interstrand crosslinks
The level of DNA interstrand crosslinking was determined
using a modiﬁcation of the comet assay (26). All steps
were carried out on ice and under subdued lighting. Brieﬂy,
5 · 10
4 cells/well were incubated overnight in 6-well plates.
Exponentially growing cells were treated with melphalan or
SJG-136 in FCS-free medium for 1 h at 37 C, and then incub-
ated in complete media as required. Cells were trypsinized and
stored at  80 C as 1 ml aliquots in a complete medium con-
taining 10% DMSO. Immediately before analysis, cells were
thawed and irradiated (12.5 Gy) to introduce a ﬁxed number of
random DNA strand breaks. Cells were mixed with 2 ml of 1%
Type-VII agarose and 1.5 ml spread over two agarose pre-
coated microscope slides. The comet assay was performed
according to established procedures (26). Slides were stained
with 2.5 mg/ml propidium iodide and comets analysed using a
Nikon inverted ﬂuorescent microscope with a high pressure
mercury light source, 510–560 nm excitation ﬁlter and 590 nm
barrier ﬁlter at 20· magniﬁcation. Twenty-ﬁve cells were
analysed per slide using Komet Assay Software (Kinetic
Imaging, Liverpool, UK).
The degree of DNA interstrand crosslinking present in a
drug-treated sample was determined by comparing the tail
moment of the irradiated drug-treated samples with irradiated
untreated samples and unirradiated untreated samples (26).
The level of interstrand crosslinking is proportional to the
decrease in the tail moment in the irradiated drug-treated sam-
ple compared to the irradiated untreated control. The decrease
in tail moment is calculated by the following formula:
% Decrease in Tail Moment DTM ðÞ
¼ 1  TMdi TMcu ðÞ / TMci TMcu ðÞ ·100
where TMdi = Mean tail moment of drug treated, irradiated
sample, TMci = Mean tail moment of irradiated control
sample, TMcu = Mean tail moment of unirradiated control
sample.
Analysis of DNA double-strand breaks by pulsed field
gel electrophoresis (PFGE)
Approximately 2 · 10
6 cells were incubated overnight in
175 cm
2 tissue culture ﬂasks. Exponentially growing cells
were treated with melphalan or SJG-136 in FCS-free medium
for 1 h at 37 C and then incubated in complete media as
required. Cells were harvested and PFGE plugs were prepared
using the Bio-Rad Mammalian CHEF Genomic Plug Kit.
PFGE was performed with 0.7% gel (Pulse Field Certiﬁed
agarose, Bio-Rad) in 0.25· TBE buffer using a Biometra
Rotaphor Type V apparatus. Electrophoresis runs were for
120 h at 14 C with the following parameters: interval
5000–1000 s log, angle 110–100  linear, voltage 50–45 V
linear. On completion, gels were stained with 2 mg/ml eth-
idium bromide for 1 h, destained overnight with water and
photographed. Semi-quantitative data were obtained by meas-
uring the absolute integrated optical density of each lane using
a Gel Pro Analyser (Media Cybernetics) and calculating the
percentage of DNA released from the DNA plug.
RESULTS
Sensitivity of NER and recombination defective cell
lines to the bi-functional ICL agents, melphalan
and SJG-136
The data presented in Figure 2 show the sensitivity of wild-
type, NER, HRR and NHEJ defective repair mutants to mel-
phalan and SJG-136, using the SRB growth inhibition assay.
When IC50 values (concentration of drug to inhibit growth
by 50%) were compared, the high cytotoxicity of SJG-136
(0.3 mM) is reﬂected by the fact that it is >100-fold more
potent in wild-type AA8 cells than melphalan (33 mM). With
both melphalan and SJG-136 cell lines defective in the
NER genes (XPB, XPD, XPG and CSB) and the NHEJ Ku
70 subunit (XRCC5) show only a modest increase in sensit-
ivity (<2-fold). In agreement with other studies, sensitivity to
both crosslinking agents was dependent on the NER repair
factors XPF-ERCC1 and the RAD51 paralogues XRCC2
and XRCC3 (12,13). After treatment with melphalan, cells
defective in XPF, ERCC1, XRCC2 and XRCC3 were highly
sensitive. IC50 values were approximately 15-, 21-, 18- and
17-foldlower,respectively,whencomparedtotheir parent cell
lines. In contrast, after treatment with SJG-136 these same
XPF, ERCC1, XRCC2 and XRCC3 defective cell lines
were approximately 7.5-, 7.5-, 7.5- and 3.5-fold more sensitive
than parent cell lines. From these data, it appears that cellular
sensitivity of the minor groove crosslinking agent SJG-136 is
dependent on XPF-ERCC1 and homologous recombination;
however, the level of sensitivity is less than with the major
groove crosslinking agent melphalan.
SensitivityofNERandrecombinationdefectivecelllines
to the mono-functional agents mono-melphalan
and mmy-SJG
Mono-melphalan and mmy-SJG are the mono-functional
counterparts of melphalan and SJG-136, respectively
(Figure 1). Neither agent can induce DNA ICLs but they
Nucleic Acids Research, 2005, Vol. 33, No. 10 3285
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 can produce mono-adducts in the major and minor groove of
DNA, respectively. In wild-type AA8 cells, the IC50 of mono-
melphalan (135 mM) and mmy-SJG (18 mM) were 4- and
60-fold higher than their bi-functional counterparts (Figure 3).
This indicates, with both classes of agent, bi-functional
adducts are a more cytotoxic form of DNA damage than
their respective mono-functional adducts. In addition, it
would suggest that mmy-SJG mono-adducts in the minor
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Figure 2. Melphalan and SJG-136 sensitivity in parental AA8, V79 and CHO-K1 cells, NER mutants XPB (UV23), XPD (UV42), XPF (UV47), CSB (UV61),
ERCC1(UV96)andXPG(UV135),recombinationmutantsXRCC2(irs1),XRCC3(irs1SF)andtheNHEJmutantXRCC5(xrs5).Growthinhibitionwasdetermined
usingtheSRBassayandthefractionofcontrolA540calculatedasdescribed.Allresultsarethemeanofatleastthreeindependentexperimentsanderrorbarsshowthe
standard error of the mean.
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 groove are more cytotoxic than melphalan mono-adducts in
the major groove.
With both mono-functional agents, NER defective CHO
cells were only 2- to 3-fold more sensitive than wild-type
cells (Figure 3). There was no extreme sensitivity of XPF
or ERCC1 cells. The HRR mutants defective in XRCC2
and XRCC3 were 17- and 13-fold more sensitive to mono-
melphalan, and 9- and 3.3-fold more sensitive to mmy-SJG.
The XRCC5 mutant defective in NHEJ was  2-fold more
sensitive than wild-type cells to the mono-functional agents.
The pattern of sensitivity of the HRR and NHEJ mutants was,
therefore, similar between the respective mono-functional and
bi-functional agents.
Clonogenic survival of NER and recombination
defective cells following melphalan and
SJG-136 treatment
SRB assays identiﬁed a difference in the relative growth
inhibition of XPF, ERCC1, XRCC2 and XRCC3 defective
cell lines to melphalan and SJG-136. Clonogenic assays were
undertaken to establish if these differences were also observed
at the level of cell killing. Clonogenic survival of AA8, and
representative defective cells UVB, ERCC1 and XRCC3 was
determined after treatment with melphalan or SJG-136.
The hypersensitivity of ERCC1 and XRCC3 defective cells
was conﬁrmed (Figure 4). A comparison of cell killing also
conﬁrms that the level of sensitivity of the ERCC1 and
XRCC3 mutants is less after treatment with SJG-136 than
with melphalan.
SJG-136 is a highly efficient crosslinking agent
We have previously demonstrated that the sensitivity of XPF
and ERCC1 defective cell lines to mechlorethamine correlates
with an inability to initiate repair by failing to unhook ICLs
(12). Using the modiﬁed comet assay, the induction and
unhooking of DNA ICLs has been investigated after treatment
with melphalan and SJG-136. Figure 5 shows the percentage
decrease in tail moment with increasing concentrations
of melphalan or SJG-136 for the wild-type AA8 cell line. A
decrease in tail moment reﬂects increased DNA interstrand
crosslinking (26). SJG-136 is a highly efﬁcient ICL agent.
Concentrations of melphalan and SJG-136 required to intro-
duce a 50% decrease in tail moment following a 1 h exposure
are  40 and 0.5 mM, respectively (Figure 5). Mono-melphalan
and mmy-SJG did not produce ICLs (data not shown).
The peak of melphalan crosslinking occurs 16–24 h after
drug treatment (9). More than 50% of the melphalan crosslinks
had been incised or ‘unhooked’ after 48 h with almost com-
plete unhooking evident after 72 h in AA8 and the NER
defective mutants XPB and XPG (Figure 6A). In agreement
with other studies using the nitrogen mustard mechloretham-
ine (12), there was little or no unhooking of melphalan ICLs in
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Figure 4. Clonogenic Survival assays for parental AA8, NER mutants XPB (UV23), ERCC1 (UV96) and the recombination mutant XRCC3 (irs1SF) cells after
treatment with melphalan or SJG-136. The surviving fraction was calculated as described. All results are the mean of two independent experiments and error bars
show the standard error of the mean.
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 XPF or ERCC1 mutants. In contrast, SJG-136 ICLs were
unhooked very slowly. With wild-type AA8 cells, >50% of
the crosslinks persisted after 72 h. There was little evidence
of repair in XPB and XPF cells, and no detectable unhooking
in the XPG and ERCC1 cells (Figure 6B). The lack of a clear
correlation between sensitivity to SJG-136 and ICL repair
capacity in the different NER mutants implies that the differ-
ential sensitivities of the NER mutants to SJG-136 is not due
to their ability to initiate repair of ICLs induced by this drug.
A comparable level of ICLs was observed in all cell lines
immediately after SJG-136 treatment demonstrating that the
differences are not due to differential induction of ICLs.
SJG-136 does not induce DNA double-strand breaks
The induction of DSBs following melphalan and SJG-136
treatment was examined in exponentially growing AA8 cells
using PFGE. There was a dose-dependent increase in lower
molecular weight DNA, representing DSB formation, imme-
diately after a 1 h treatment with different concentrations of
melphalan between 10 and 50 mM (Figure 7). No DSBs were
observed following treatment with SJG-136 concentrations
up to 1.5 mM (ﬁve times the IC50) (Figure 7). Furthermore,
no DSBs were observed at any time up to 24 h after 1.5 mM
SJG-136 treatment (data not shown). In agreement with
results generated with mechlorethamine (12), cells defective
in homologous recombination (XRCC3) are defective in the
repair of DSBs associated with melphalan ICLs (Figure 8).
Repair of these DSBs is similar to the wild-type cells in the
sensitive ERCC1 mutant. A dose of 30 mM melphalan was
used to investigate the repair of ICL associated DNA DSBs.
With an equimolar dose of mono-melphalan no DNA DSBs
were observed, indicating that these DSBs are dependent on
the presence of ICLs (data not shown).
DISCUSSION
These results conﬁrm previous reports that bi-functional
agents are more cytotoxic than their mono-functional ana-
logues (27). The increased cytotoxicity and clinical efﬁcacy
of bi-functional agents is associated with their ability to pro-
duce DNA interstrand crosslinks. The minor groove binding
bi-functional agent SJG-136 exhibits potent cytotoxicity and
is a highly efﬁcient crosslinking agent. Its mono-functional
analogue mmy-SJG is also highly cytotoxic compared to
the major groove binding melphalan or mono-melphalan.
Similarly, other minor groove mono-functional alkylating
agents such as tallimustine and CC-1065 have shown higher
cytotoxicity than more conventional major groove binding
agents (11).
With bi-functional ICL agents, the XPF-ERCC1-speciﬁc
nuclease has been demonstrated to play a critical role leading
to the repair of ICLs both in vivo and in vitro (1,12,13,15).
A possible model for ICL repair in mammalian cells is that
the XPF-ERCC1-speciﬁc nuclease initiates repair by making
dual incisions ﬂanking the crosslink that ‘unhook’ or release
the lesion in the form of an oligonucleotide attached to the
complementary DNA strand (12,28). Re-section of the gap
produced by ICL incision in a 50–30 direction would then
produce a suitable substrate for homologous recombination.
This model is consistent with the results presented here in that
XPF-ERCC1 mutants do not show extreme sensitivity to
mono-melphalan or mmy-SJG compared to their respective
bi-functional analogues. However, the XRCC2 and XRCC3
HRR defective mutants show a similar, increased sensitivity to
both the mono-functional and bi-functional paired agents used
in this study. It would appear that HRR is required for the
downstream repair of unhooked and re-sectioned ICLs and for
the repair of their equivalent mono-adducts.
Cytotoxicity data indicate that SJG-136 minor groove cross-
links are recognized and repaired in a manner similar to that of
melphalan (this study) and other major groove crosslinking
agents (1,12,13) in that a combination of XPF-ERCC1 and
HRR is required. However, the extent of sensitivity of XPF,
ERCC1, XRCC2 and XRCC3 mutants to SJG-136 is signiﬁc-
antly less than for melphalan or to other major groove cross-
linking agents such as mechlorethamine and cisplatin (12,13).
The XPF, ERCC1, XRCC2 and XRCC3 defective mutants
were 7.5, 7.5, 7.5 and 3.5 times more sensitive than parent
cell lines to SJG-136. With melphalan, mechlorethamine or
cisplatin, all mutants were at least 15 times more sensitive and
in some instances >40 times more sensitive than parent cell
lines (12,13). This indicates that SJG-136 cytotoxicity is less
dependent on XPF-ERCC1 and HRR factors than melphalan
or other more conventional major groove crosslinking agents.
A possible explanation for these differences is that minor
groove alkylating agents do not cause as much DNA helix
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 distortion as major groove binders. Major groove crosslinking
agents such as cisplatin induce a high degree of helical dis-
tortion (29). Molecular modelling of an SJG-136 crosslink in
the minor groove of DNA shows very little helical distortion
(30,31). Since helical distortion or changes in chromatin struc-
ture are major DNA motifs recognized by many DNA repair
proteins (32,33), minor groove DNA damage and crosslinks
would be less well recognized and repaired less readily. It
might be expected that poor recognition of minor groove
DNA damage would result in less dependency for repair pro-
cesses and result in greater cytotoxicity. Not only is SJG-136
a highly cytotoxic and efﬁcient crosslinking agent, repair of
SJG-136 ICLs in the minor groove is much slower than for
those formed in the major groove by melphalan.
With melphalan, there is a direct correlation between XPF
and ERCC1 mutant sensitivity and the ability to unhook mel-
phalan ICLs. The mechanism of incision of melphalan ICLs
appears to be the same as that for mechlorethamine (12).
However, with SJG-136 there is no clear correlation between
cellular sensitivity and the ability to unhook ICLs. Despite
showing only modest increased sensitivity, there is little
unhooking of SJG-136 ICLs by XPB or XPG mutants. The
same situation has been reported in NER-defective CHO cells
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Figure 6. Kinetics of unhooking of (A) melphalan and (B) SJG-136 induced ICLs in parent (AA8) and NER mutant cell lines; XPB (UV23), XPG (UV135), XPF
(UV47) and ERCC1 (9UV96). Cells were treated with 30 mM melphalan or 0.3 mM SJG-136 for 1 h, incubated in fresh medium and the level of ICLs measured at
specific time points using the modified comet assay. Results are the mean of three independent experiments and error bars show the standard error of the mean.
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of either compound for 1 h, and DSBs analysed immediately by PFGE.
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 treated with cisplatin (13). Cisplatin ICLs are, however,
incised efﬁciently in wild-type cells, and this requires the
full NER apparatus (13). In contrast, SJG-136 ICLs are not
incised to any great extent over a 72 h period in wild-type or
NER-defectivecells.TheincreasedsensitivityofXPF-ERCC1
mutants to SJG-136 would therefore appear to suggest a role
in a HR-dependent repair pathway. Our data and that of
other workers (12,14–17) would suggest that the role of the
ERCC1-XPFendonuclease complexinICLrepairistounhook
the crosslink and catalyse subsequent resectioning reactions to
provide a suitable repair intermediate which can be processed
further by HRR.
The signiﬁcance of DNA DSB formation following treat-
ment with ICL agents is unknown. Nitrogen mustards includ-
ing melphalan induce DNA DSBs (12). The maximum yield of
DNA DSBs is immediately after drug treatment and these
DSBs are repaired rapidly in a HRR-dependent manner.
This is in contrast to the relatively slow repair of melphalan
ICLs. Consideration of the differential induction and repair
rates of melphalan-induced DSBs and ICLs make it unlikely
that the DSBs are arising as ICL repair intermediates. It is
more likely that in cells, melphalan-induced DSBs are formed
as a result of stalled replication forks in the vicinity of
melphalan ICLs as suggested by studies with different cross-
linking agents (12). It is intriguing why no ICL associated
DNA DSBs are detected by PFGE after treatment with
SJG-136 (this study) or cisplatin (13). Although it remains
to be resolved, a possible explanation for the lack of DSB
induction by SJG-136 is that, due to the lack of helical dis-
tortion, SJG-136 ICLs could be good substrates for replication
bypass. Mechanisms for the replication bypass of ICLs have
been reported [(34) and references within].
Collectively, these studies indicate that there are differences
in the processing of ICLs produced by different drugs. In
the case of SJG-136, the high level of cytotoxicity is likely
to result from the poor recognition of DNA damage by repair
proteins leading to the slow repair of both mono-adducts and
more importantly ICLs in the minor groove. While HRR
clearly contributes to the repair of SJG-136 ICLs and
mono-adducts, of particular note is the differential sensitivity
between the XRCC2 and XRCC3 mutants. Only with the
minor groove binding agents SJG-136 and mmy-SJG did
the XRCC3 mutants exhibit signiﬁcantly lower levels of
cytotoxicity than XRCC2 mutants. During homologous
recombination, at least two stable complexes have been iden-
tiﬁed: a dimeric complex composed of XRCC3 and Rad51C
and a larger complex composed of XRCC2, Rad51B, Rad51C
and Rad51D (35,36). While the exact roles of these separate
complexes remain unclear, it may be that the repair of minor
groove DNA damage is more dependent on the complex
containing XRCC2.
In conclusion, homologous recombination repair plays an
essential role in the protection against both major groove and
minor groove DNA interstrand crosslinking agents. There are
a number of cancer-prone genetic disorders involving proteins
required for or associated with homologous recombination.
These include ataxia telangiectasia, Nijmegen breakage syn-
drome, Blooms syndrome and Fanconi anemia (37). Genes
involved in homologous recombination are tumour suppressor
genes and mutations in BRCA1, BRCA2 and Rad51 have
been identiﬁed and associated with speciﬁc cancers (37).
Collectively, this suggests that speciﬁc tumours are likely
to be defective in HRR and that targeting the HRR pathway
withspeciﬁcchemotherapeuticsmayresultinselectivetumour
cytotoxicity.
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